BridgeMD
New treatment option for Liver
Official title Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection
ClinicalTrials.gov ID: NCT05879159
What this study is testing
- What it's testing
- To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below)
- No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results)
- No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection
- Ability to stay within 50 miles of medical center for immediate postop period
- Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for...
You likely can't join if
- Patients who will be excluded include those with:
- Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy
- Tumors not amenable to MIS or Robotic-assisted surgical resection
- Evidence of Cirrhosis on imaging, clinically, or lab testing
- Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period
- Age below 18 years
See the full eligibility criteria
- Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below)
- No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results)
- No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection
- Ability to stay within 50 miles of medical center for immediate postop period
- Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \<18 years of age, children are excluded from this study
- Ability to understand and the willingness to sign a written informed consent document
- Non-English-speaking patients are eligible for participation
- Patients who will be excluded include those with:
- Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy
- Tumors not amenable to MIS or Robotic-assisted surgical resection
- Evidence of Cirrhosis on imaging, clinically, or lab testing
- Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period
- Age below 18 years
- Inability to consent for trial/protocol
- Patients who are pregnant
The study team makes the final eligibility decision.
Where it's taking place
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.